Immunome IMNM Cash Flow Statement (2019-2026)

NASDAQ IMNM
$26.75 -0.41 (-1.51%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Immunome Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Immunome reported cash from operations of -$61.69M and free cash flow of -$63.87M for the quarter ended Jun 2026, down 24.9% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-7.72M-7.84M-11.65M-8.93M-8.53M-7.79M-4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M-72.86M-59.33M-78.14M
Share-based CompensationStock Comp.
1.94M1.22M2.01M2.53M2.51M1.35M2.49M3.04M3.02M2.88M8.53M8.54M4.89M5.47M5.70M5.35M87.40M7.89M81.70M89.80M
Gains from Investment SecuritiesGains Investment
Cash from OperationsCash from Ops.
-4.14M-6.80M-6.38M-8.06M-7.57M-6.68M24.17M-5.67M-8.61M-17.46M-11.17M-23.40M-34.17M-42.06M-53.05M-49.40M-40.51M-47.95M-58.64M-61.69M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.03M0.01M0.01M0.17M0.05M0.06M-0.44M0.84M0.54M0.35M1.47M0.54M0.82M1.21M0.82M0.15M0.30M
Depreciation & Amortization (CF)Dep. & Amort.
0.29M0.16M0.11M0.11M0.10M0.10M0.09M0.10M0.11M0.19M0.16M0.55M0.41M0.48M0.61M0.64M0.59M0.66M0.60M0.96M
Change in Working Capital
Change in Account PayablesChange Payables
1.60M-0.31M0.79M1.39M-2.12M-0.74M0.69M0.59M-1.21M-0.68M2.40M-0.03M-2.11M9.27M-3.81M-4.95M1.87M-2.28M1.42M1.19M
Change in Accured ExpensesChange Accured Exp.
2.50M2.47M-0.91M-2.43M0.87M0.55M-1.40M1.37M-1.42M2.07M0.67M6.90M5.94M0.04M-8.52M0.62M6.74M5.70M-9.75M7.90M
Other Working Capital ChangesOther WC Changes
27.64M-4.26M-3.56M-3.83M-1.03M-2.36M-2.91M-2.74M-2.93M-4.01M
Investing Activities
Capital ExpendituresCapex
0.03M0.01M0.01M0.17M0.07M0.22M0.22M0.04M0.35M2.16M2.34M1.54M1.13M3.67M0.91M1.12M4.00M3.00M2.18M
Change in Acquisitions & DivestmentsChange Acquisitions
30.00M85.00M15.00M60.00M125.00M
Cash from Investing ActivitiesCash from Investing
-0.03M-0.01M-0.01M-0.17M-0.07M-0.11M-0.34M-0.04M-30.00M-37.23M-81.69M24.10M9.76M5.09M-64.17M123.88M-4.00M-12.02M-304.35M
Financing Activities
Other financing activitiesOther financing
0.05M0.03M0.03M64.00M3.43M0.30M0.21M0.21M0.41M0.07M0.23M1.06M
Cash from Financing ActivitiesCash from Financing
0.58M-0.20M0.03M0.03M60.88M55.50M219.44M0.69M0.30M20.09M162.23M-0.06M45.39M432.80M-0.14M1.06M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.80M0.02M0.56M0.05M4.01M1.13M6.62M0.35M5.56M0.50M
Net Equity Issued and RepurchasedNet Equity Issued
0.03M125.00M20.00M44.90M0.43M
Additional items
Change in Cash
-3.59M-7.01M-6.35M-8.23M-7.57M-6.75M24.10M-6.01M52.23M8.04M171.04M-104.39M-9.76M-12.22M114.26M-113.63M128.76M380.84M-70.79M-364.99M
Free Cash FlowFCF
-4.17M-6.82M-6.38M-8.23M-7.57M-6.75M23.95M-5.89M-8.65M-17.81M-13.33M-25.74M-35.71M-43.19M-56.72M-50.31M-41.63M-51.95M-61.64M-63.87M
Net Cash FlowNCF
-3.59M-7.01M-6.35M-8.23M-7.57M-6.75M24.10M-6.01M52.23M8.04M171.04M-104.39M-9.76M-12.22M114.26M-113.63M128.76M380.84M-70.79M-364.99M